← Leaderboards
Jingwei Cheng
Dana-Farber Cancer Inst
$901,840
Attributed
$901,840
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $191.9K · FY2019–25$200K$150K$100K$50K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$901,840 · 2
By mechanism
P20$573,964 · 1
R50$327,876 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Merkel Cell Carcinoma”
- Ted Gooley · Fred Hutchinson Cancer Center$1,998,608
- Ling Gao · Veterans Health Administration$1,511,555
- Monique Elise Verhaegen · University Of Michigan At Ann Arbor$1,464,796
- Derin B Keskin · Dana-Farber Cancer Inst$1,438,870
- Michael J Shamblott · Morphogenesis, Inc.$400,000
- Thomas Pulliam · University Of Washington$167,597
Research focus
Merkel Cell CarcinomaInsightViralViral AntigensMerkel CellsMalignant NeoplasmsMelanomaMutationTumorigenesisVirusPolyomavirusOncogenicAutomobile DrivingNeurosecretory SystemsCancer Drug ResistanceCombatCancer Clinical TrialBiomedical EngineeringArginineConventional TherapyCell SecretionBiologyChip-SeqClinical Trials
Grant awards (5)
Targeting PRMT5 to combat cancer drug resistance associated with neuroendocrine differentiation$190,768
P20 · FY2025 · GM · contact PI
Targeting PRMT5 to combat cancer drug resistance associated with neuroendocrine differentiation$191,321
P20 · FY2024 · GM · contact PI
Targeting PRMT5 to combat cancer drug resistance associated with neuroendocrine differentiation$191,875
P20 · FY2023 · GM · contact PI
Validation of EP400 downstream effectors and potential therapeutic targets in Merkel cell carcinoma$163,938
R50 · FY2020 · CA · contact PI
Validation of EP400 downstream effectors and potential therapeutic targets in Merkel cell carcinoma$163,938
R50 · FY2019 · CA · contact PI